Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI), also called primary ovarian insufficiency, is the loss of normal ovarian function before age 40, marked by amenorrhea or oligomenorrhea together with elevated gonadotropins and low estradiol. It is the hypergonadotropic, hypo-estrogenic category of ovulatory disorder and a cause of anovulatory infertility.

Definition

Premature ovarian insufficiency is the cessation or marked impairment of ovarian function before age 40, defined by menstrual disturbance with elevated follicle-stimulating hormone and low estradiol, reflecting depletion or dysfunction of ovarian follicles.

Scope

This topic covers the definition and diagnostic features of POI, its hormonal signature, its principal causes, and how it differs from natural menopause and from hypothalamic causes of amenorrhea. It is a reference overview, not a clinical management protocol.

Core questions

• What distinguishes premature ovarian insufficiency from natural menopause and from hypothalamic amenorrhea?
• Which genetic, autoimmune, iatrogenic, and idiopathic causes underlie POI?
• Why is POI characterized as a hypergonadotropic state?

Key concepts

• Hypergonadotropic hypogonadism
• Elevated follicle-stimulating hormone (FSH)
• Follicle depletion versus follicle dysfunction
• Genetic causes (e.g., Turner syndrome, fragile X premutation)
• Autoimmune oophoritis
• Iatrogenic causes (chemotherapy, radiotherapy, surgery)
• Intermittent and unpredictable ovarian function

Mechanisms

POI arises when the ovary can no longer sustain normal folliculogenesis, either because the follicle pool is depleted or because remaining follicles function abnormally. As ovarian estradiol and inhibin fall, the negative feedback on the pituitary is lost, so FSH and LH rise — the hypergonadotropic, hypo-estrogenic pattern that defines the condition. Causes are heterogeneous and include chromosomal and single-gene disorders such as Turner syndrome and the fragile X premutation, autoimmune oophoritis, and iatrogenic injury from chemotherapy, radiotherapy, or surgery; many cases remain idiopathic. Unlike menopause, residual ovarian activity in POI can be intermittent, so ovulation occasionally resumes.

Clinical relevance

POI is an important cause of anovulation and early estrogen deficiency, with implications that distinguish it from both reversible hypothalamic amenorrhea and physiological menopause. This entry describes the condition for educational orientation and is not a basis for individual diagnosis, fertility counseling, or hormone-replacement decisions.

Epidemiology

Premature ovarian insufficiency affects roughly one in a hundred women by age 40, with prevalence increasing with age across the reproductive years; a substantial proportion of cases are idiopathic, while identifiable causes include genetic, autoimmune, and iatrogenic factors.

History

Loss of ovarian function before the expected age of menopause was historically termed premature ovarian failure, but the recognition that ovarian activity can be intermittent rather than absent led to the preferred terms primary or premature ovarian insufficiency, reflected in modern reviews and the 2016 ESHRE guideline.

Debates

Terminology: insufficiency versus failure

Because some women with the condition retain intermittent, unpredictable ovarian function and may occasionally ovulate, the term insufficiency is preferred over failure to avoid implying a complete and irreversible loss of function.

Key figures

• Lawrence Nelson

Seminal works

• nelson-2009
• eshre-poi-2016

Frequently asked questions

How does premature ovarian insufficiency differ from menopause?

Both involve declining ovarian function with high FSH and low estradiol, but POI occurs before age 40 and ovarian activity can be intermittent, so occasional ovulation and even pregnancy remain possible, unlike established menopause.

Why is POI called hypergonadotropic?

Because the failing ovary produces less estradiol and inhibin, the pituitary loses negative feedback and secretes high levels of FSH and LH, the hallmark of a hypergonadotropic, hypo-estrogenic disorder.